ALBANY, N.Y., March 17, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced expansion plans to its Glasgow, UK facility and [...] Read more »
Curia annonce l’extension de son réseau mondial de sites de remplissage et de finition stériles
ALBANY, État de New York, 17 mars 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), une organisation leader du domaine de la recherche, du développement et de la fabrication sous contrat, dévoile ce jour les [...] Read more »
OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders
MIAMI and JERUSALEM, March 17, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, entered into [...] Read more »
VIVUS تطلق عقار QSYMIA® في الإمارات العربية المتحدة
– علاج جديد في Read more »
VIVUS Launches QSYMIA® in the United Arab Emirates
– A new path in weight management is now available
– UAE is the first country in the Middle East to have QSYMIA® available
Read more »
Curia Anuncia Refinanciamento Estratégico em Apoio ao Crescimento Contínuo
ALBANY, N.Y., March 08, 2025 (GLOBE NEWSWIRE) — A Curia Global, Inc. (Curia), uma organização líder em contratos de pesquisa, desenvolvimento e fabricação, anunciou hoje que refinanciou suas linhas [...] Read more »
Curia kündigt strategische Refinanzierung zur Unterstützung weiteren Wachstums an
ALBANY, N.Y., March 08, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), ein führendes Auftragsforschungs–, Entwicklungs– und Produktionsunternehmen, gab heute bekannt, dass es seine vorrangig gesicherten [...] Read more »
Curia annonce un refinancement stratégique visant à soutenir la poursuite de sa croissance
ALBANY, New York, 08 mars 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), l’une des principales organisations de recherche, de développement et de fabrication sous contrat, a annoncé aujourd’hui le [...] Read more »
Curia Announces Strategic Refinancing to Support Continued Growth
ALBANY, N.Y., March 07, 2025 (GLOBE NEWSWIRE) — Curia Global, Inc. (Curia), a leading contract research, development and manufacturing organization, today announced it has refinanced its senior secured credit [...] Read more »
Society for Clinical Research Sites (SCRS) und Fortrea gehen eine Partnerschaft zur Förderung der Zusammenarbeit in der klinischen Forschung ein
DURHAM, North Carolina, Feb. 20, 2025 (GLOBE NEWSWIRE) — Die Society for Clinical Research Sites (SCRS) und Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization, [...] Read more »
La Society for Clinical Research Sites (SCRS) et Fortrea s’associent pour promouvoir la collaboration dans le domaine de la recherche clinique
DURHAM, N.C., 20 févr. 2025 (GLOBE NEWSWIRE) — La Society for Clinical Research Sites (SCRS) et Fortrea (Nasdaq : FTRE), l’une des principales organisations de recherche contractuelle (ORC) à [...] Read more »
Society for Clinical Research Sites (SCRS) e Fortrea Fazem Parceria para Promover a Colaboração na Pesquisa Clínica
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — A Society for Clinical Research Sites (SCRS) e a Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), tem o prazer de anunciar o [...] Read more »
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s [...] Read more »
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
JERUSALEM , Feb. 19, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet [...] Read more »
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
– Advancing Phase 2 and Phase 3 trials of obexelimab, a unique CD–19 x FcγRIIb inhibitor of B cell function–
–Topline results from Phase 2 Trial in [...] Read more »